SABCS 2022 | NeoMono: mono atezolizumab window followed by atezolizumab – CTX vs atezolizumab – CTX

Hans-Christian Kolberg, MD, Marien Hospital Bottrop, Bottrop, Germany, discusses an interim analysis of the Phase II NeoMono (NCT04770272) neoadjuvant trial investigating the comparison of a mono atezolizumab window followed by atezolizumab and chemotherapy with atezolizumab and chemotherapy in triple-negative breast cancer (TNBC). The Phase III KEYNOTE-522 (NCT03036488) trial demonstrated the addition of an immune checkpoint inhibitor (ICI) to neoadjuvant chemotherapy had a beneficial impact on event-free survival (EFS) even in patients who did not achieve a pCR. In the Phase II GeparNuevo (NCT02685059) trial only those patients with TNBC who received a 2-week ICI monotherapy window before the start of neoadjuvant chemotherapy in combination with checkpoint inhibition, achieved a significant pCR benefit from the addition of durvalumab to neoadjuvant chemotherapy alone. The primary endpoint of the NeoMono trial was pathologic complete response (pCR). No difference in pCR was observed between the two arms at the interim analysis. However, in an exploratory analysis, a subset of patients with high PD-L1 expression, the results were positive, demonstrating a pCR rate of 100% in the window group. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.